odm-208
orion pharma,orion
['crpc', 'cypides', 'prostate', 'odm-208 ']
 demonstrated the preliminary phase ii results of the odm-208 cypides study in patients with metastatic castration-resistant #prostatecancer (mcrpc) at the 2022 meeting. visit for more insights: #esmo2022 #esmo #esmo22 
#DelveInsight is a premier Business Consulting and Market Research firm, focused exclusively on the healthcare industry